Gracell Biotechnologies Stock Net Income
Gracell Biotechnologies fundamentals help investors to digest information that contributes to Gracell Biotechnologies' financial success or failures. It also enables traders to predict the movement of Gracell Stock. The fundamental analysis module provides a way to measure Gracell Biotechnologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gracell Biotechnologies stock.
Gracell |
Gracell Biotechnologies Company Net Income Analysis
Gracell Biotechnologies' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Gracell Biotechnologies Net Income | (496.98 M) |
Most of Gracell Biotechnologies' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gracell Biotechnologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Gracell Biotechnologies reported net income of (496.98 Million). This is 245.62% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 187.04% higher than that of the company.
Gracell Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gracell Biotechnologies' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gracell Biotechnologies could also be used in its relative valuation, which is a method of valuing Gracell Biotechnologies by comparing valuation metrics of similar companies.Gracell Biotechnologies is currently under evaluation in net income category among its peers.
Gracell Fundamentals
| Return On Equity | -0.32 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | 3.32 B | |||
| Shares Outstanding | 96.57 M | |||
| Shares Owned By Insiders | 16.39 % | |||
| Shares Owned By Institutions | 63.11 % | |||
| Number Of Shares Shorted | 1.19 M | |||
| Price To Book | 4.39 X | |||
| Price To Sales | 732.21 X | |||
| Gross Profit | 366 K | |||
| EBITDA | (509.64 M) | |||
| Net Income | (496.98 M) | |||
| Cash And Equivalents | 1.71 B | |||
| Cash Per Share | 25.28 X | |||
| Total Debt | 182.98 M | |||
| Debt To Equity | 0.11 % | |||
| Current Ratio | 8.01 X | |||
| Book Value Per Share | 16.90 X | |||
| Cash Flow From Operations | (482.65 M) | |||
| Short Ratio | 0.87 X | |||
| Earnings Per Share | (0.97) X | |||
| Target Price | 10.58 | |||
| Number Of Employees | 314 | |||
| Beta | -0.34 | |||
| Market Capitalization | 989.87 M | |||
| Total Asset | 1.66 B | |||
| Retained Earnings | (1.63 B) | |||
| Working Capital | 1.28 B | |||
| Z Score | 1.78 | |||
| Net Asset | 1.66 B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in Gracell Stock
If you are still planning to invest in Gracell Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gracell Biotechnologies' history and understand the potential risks before investing.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |